Suppr超能文献

一种用于评估人多瘤病毒JC DNA载量的定量聚合酶链反应检测方法的开发与应用

Development and utilization of a quantitative polymerase chain reaction assay to evaluate human polyomavirus JC DNA load.

作者信息

Cavallo R, Bergallo M, Costa C, Piana F, Burdino E, Merlino C, Negro Ponzi A

机构信息

Virology Unit, Department of Public Health and Microbiology, University of Turin, Turin, Italy.

出版信息

Panminerva Med. 2006 Mar;48(1):59-66.

Abstract

AIM

Quantitative polymerase chain reaction (PCR) analysis to evaluate virus load in comparison with the patient's base-line virus levels would be an optimal diagnostic approach to monitoring human polyomavirus infections and to investigate their possible involvement in the onset of nephropathy in this patient group. Studies on the correlation between viral burden and renal disease have pointed to the incidence of JC virus (JCV) related progressive multifocal leukoencephalopathy (PML) occurring in renal and haematopoietic stem cell transplant recipients.

METHODS

We developed a reliable internally-controlled quantitative PCR assay to measure JCV-DNA in fluid samples of urine, serum and cerebrospinal fluid (CSF) by densitometric analysis of the amplification products. The assay was also used to evaluate the JCV load in CFS samples from patients with suspected demyelinating syndrome and in urine and serum samples from healthy subjects and renal transplant recipients.

RESULTS

All CSF samples from the 51 patients with suspected demyelinating syndrome tested JCV-DNA negative: none of them had a diagnosed PML. Analysis of the prevalence of JCV-viruria and JCV-viraemia confirmed our previous data. JCV-viruria was detected in 17% of renal transplant recipients and 26.6% of healthy controls; JCV-viraemia was found in 3.4% of transplant patients and 0% in controls. Noteworthy was a lower prevalence of JCV-viraemia in the 116 (3.4%) renal transplant patients than the prevalence previously reported for the 51 (11.8%) patients with suspected demyelinating syndrome. The mean viral load of viruria was much higher in the healthy controls than in the transplant recipients [104020 DNA copies/mL (DS+/-62284) vs 4136 DNA copies/mL (DS+/-77371)].

CONCLUSIONS

The quantitative PCR assay developed in our lab offers in 2 h time a reliable true quantification of viral DNA by densitometric analysis of the amplification product. To check for the possible presence of potential Taq polymerase inhibitors an internal control (the homemade pJCV-C plasmid) is used. The relation between polyomavirus infections and their possible involvement in post-transplant pathologies need further investigation. It would be useful to monitor the JCV-DNA load in urine and serum from more renal transplant recipients, including patients with nephropathy or active graft rejection over a longer period of time.

摘要

目的

定量聚合酶链反应(PCR)分析用于评估病毒载量,并与患者的基线病毒水平进行比较,这将是监测人类多瘤病毒感染以及调查其在该患者群体肾病发病中可能作用的最佳诊断方法。关于病毒载量与肾脏疾病之间相关性的研究指出,JC病毒(JCV)相关的进行性多灶性白质脑病(PML)在肾移植和造血干细胞移植受者中的发病率。

方法

我们开发了一种可靠的内部对照定量PCR检测方法,通过对扩增产物进行光密度分析来测量尿液、血清和脑脊液(CSF)液体样本中的JCV-DNA。该检测方法还用于评估疑似脱髓鞘综合征患者的脑脊液样本以及健康受试者和肾移植受者的尿液和血清样本中的JCV载量。

结果

51例疑似脱髓鞘综合征患者的所有脑脊液样本检测JCV-DNA均为阴性:他们中没有人被诊断为PML。对JCV病毒尿症和JCV病毒血症患病率的分析证实了我们之前的数据。在17%的肾移植受者和26.6%的健康对照中检测到JCV病毒尿症;在3.4%的移植患者中发现JCV病毒血症,而对照组中未发现。值得注意的是,116例(3.4%)肾移植患者中JCV病毒血症的患病率低于先前报道的51例(11.8%)疑似脱髓鞘综合征患者的患病率。健康对照中病毒尿症的平均病毒载量远高于移植受者[104020 DNA拷贝/mL(DS±62284)对4136 DNA拷贝/mL(DS±77371)]。

结论

我们实验室开发的定量PCR检测方法通过对扩增产物进行光密度分析,在2小时内可提供可靠的病毒DNA真实定量。为检查潜在的Taq聚合酶抑制剂的可能存在,使用了内部对照(自制的pJCV-C质粒)。多瘤病毒感染与其在移植后病理中可能的作用之间的关系需要进一步研究。监测更多肾移植受者(包括患有肾病或有活跃移植排斥反应的患者)尿液和血清中的JCV-DNA载量,在更长时间内进行将是有用的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验